News Releases

Patients Can Now Be Removed from Respiratory Isolation Following One or Two Negative Xpert MTB/RIF Results

Fourth Quarter Commercial Clinical Up 26% Driven by 29% Growth in Xpert® Reagents

Quantitative Test for Rapid Measurement of the HIV-1 Viral Load in Plasma Delivers Individual Results in About 90 Minutes

Accurate Norovirus Detection in as Little as One Hour

Redundant targets extend coverage for detection of seasonal and emerging novel viruses

With Funding from the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, Cepheid Expects to Deliver Prototype in as Little as Eight Weeks

Commercial Clinical Grows 23% Driven by 25% Growth in Xpert Tests

Acquires Customer Relationships from Former Distribution Partner

First molecular test indicated for samples from both males and females

Redundant targets extend coverage to provide detection of seasonal and emerging novel viruses

No Customer or Revenue Impact Expected

Program to Enable Broader Access to Groundbreaking Tuberculosis Diagnostic

Record HBDC Placements and Strength in North America Reagents Drive 27% Clinical Growth

Carbapenem Resistance Consortium Includes AstraZeneca, Cepheid, Cubist, and GSK

On-demand molecular test detects and differentiates the genes encoding the most prevalent carbapenemases: KPC, NDM, VIM, OXA-48 and IMP-1